GRDX - Entero Therapeutics, Inc.

2.42
-0.370   -15.289%

Share volume: 203,774
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$2.79
-0.37
-0.13%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 42%
Liquidity 27%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-16.26%
1 Month
14.69%
3 Months
-31.83%
6 Months
-44.75%
1 Year
571.85%
2 Year
-16.84%
Key data
Stock price
$2.42
P/E Ratio 
0.00
DAY RANGE
$2.35 - $2.89
EPS 
-$1.83
52 WEEK RANGE
$0.32 - $5.84
52 WEEK CHANGE
$568.69
MARKET CAP 
7.943 M
YIELD 
N/A
SHARES OUTSTANDING 
3.362 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-20-2025
BETA 
3.42
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$146,670
AVERAGE 30 VOLUME 
$101,558
Company detail
CEO: James E. Sapirstein
Region: US
Website: www.enterothera.com
Employees: 9
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Recent news